Synonym
Aza-T-dCyd; AzaT-dCyd; Aza T-dCyd; Aza-TdCyd; Aza-T dCyd; Aza T dCyd; AzaTdCyd;
IUPAC/Chemical Name
4-amino-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-2-yl)-1,3,5-triazin-2(1H)-one
InChi Key
HOOZQNOZVFCJNL-KVQBGUIXSA-N
InChi Code
InChI=1S/C8H12N4O3S/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1
SMILES Code
OC[C@@H]1[C@@H](O)C[C@H](N2C=NC(N)=NC2=O)S1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
244.27
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Parker WB, Thottassery JV. 5-Aza-4'-thio-2'-deoxycytidine, a New Orally Bioavailable Nontoxic "Best-in-Class": DNA Methyltransferase 1-Depleting Agent in Clinical Development. J Pharmacol Exp Ther. 2021 Nov;379(3):211-222. doi: 10.1124/jpet.121.000758. Epub 2021 Sep 9. PMID: 34503994.
2: Morris J, Wishka DG, Lopez OD, Rudchenko V, Huang G, Hoffman SN, Borgel S, Georgius K, Carter J, Stotler H, Kunkel MW, Collins JM, Hollingshead MG, Teicher BA. F-aza-T-dCyd (NSC801845), a Novel Cytidine Analog, in Comparative Cell Culture and Xenograft Studies with the Clinical Candidates T-dCyd, F-T-dCyd, and Aza-T-dCyd. Mol Cancer Ther. 2021 Apr;20(4):625-631. doi: 10.1158/1535-7163.MCT-20-0738. PMID: 33811149; PMCID: PMC8030693.
3: Wishka DG, Lopez OD, Rudchenko VF, Huang G, Bahde R, Kumar V, Denysenko SM, Zhang L, Zhang M, Teicher BA, Morris J. The development of β-selective glycosylation reactions with benzyl substituted 2-deoxy-1,4-dithio-D-erythro-pentofuranosides: enabling practical multi- gram syntheses of 4'-Thio-2'-deoxycytidine (T-dCyd) and 5-aza-4'-thio-2'-deoxycytidine (aza-T-dCyd) to support clinical development. Nucleosides Nucleotides Nucleic Acids. 2021;40(1):68-95. doi: 10.1080/15257770.2020.1832694. Epub 2020 Oct 16. PMID: 33063584.
4: Thottassery JV, Sambandam V, Allan PW, Maddry JA, Maxuitenko YY, Tiwari K, Hollingshead M, Parker WB. Novel DNA methyltransferase-1 (DNMT1) depleting anticancer nucleosides, 4'-thio-2'-deoxycytidine and 5-aza-4'-thio-2'-deoxycytidine. Cancer Chemother Pharmacol. 2014 Aug;74(2):291-302. doi: 10.1007/s00280-014-2503-z. Epub 2014 Jun 8. PMID: 24908436; PMCID: PMC4194194.
